Biden Budget Gives Drug Pricing Reform A Spotlight But No Specifics
Approach leaves policy development to Congress. The President understands the need to build consensus around specific policies to achieve his goals, White House Office of Management and Budget Acting Director Shalanda Young explains.
You may also be interested in...
White House confirms that it will not be pushing major drug pricing provisions to help pay for its next multi-trillion dollar legislative proposal. That sounds like good news for industry – but don’t pop the champagne just yet.
As stakeholders begin to mull the impact of the Arthrex opinion, HHS withdraws its advisory opinion concluding manufacturers are legally bound to provide 340B discounts to contract pharmacies, and Lilly takes aim at 340b contract pharmacy ‘replenishment’ model.
Sens. Durbin and Grassley hope report will help revive their flagging legislation that would require Rx ads to include list prices Senators claim that the Government Accountability Office concludes that direct-to-consumer spots for prescription drugs drives ‘drastic’ increases in Medicare costs.